Padcev Injection, Powder, Lyophilized, For Solution
Product Images NDC 51144-030

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Padcev (NDC 51144-030). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Seagen Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Enfortumab Vedotin Structural Formula (Image 01)

Chemical structure diagram showing components of the drug-linker conjugate of Enfortumab Vedotin, including AGS-22C3, PABC (p-aminobenzyl alcohol carbamate), valine-citrulline dipeptide, and the cytotoxic agent SGD-1010 (MMAE). The image details the molecular arrangement and bond connectivity of these components.*

FDA Label Image

Padcev (enfortumab Vedotin-ejfv) For Injection 20 mg/vial Label (Image 02)

Packaging label for PADCEV (enfortumab vedotin-ejfvy) injection, powder, lyophilized, for solution, 20 mg/vial. The label specifies it is for intravenous use, single-dose vial, requiring reconstitution and dilution before use. Labeled with warnings for cytotoxic agent use. Manufactured and distributed by Astellas Pharma US, Inc. and Seagen Inc. Includes storage instructions and barcode.*

FDA Label Image

Padcev (enfortumab Vedotin-ejfv) For Injection 30 mg/vial Label (Image 03)

Packaging label for PADCEV (enfortumab vedotin-ejfv) injection, powder, lyophilized, for solution, 30 mg/vial. The label shows it is for intravenous use, a cytotoxic agent, single-dose vial, and must be reconstituted and diluted before use. Manufactured by Astellas and distributed by Seagen Inc. Storage instructions specify refrigeration at 2°C to 8°C. The label includes barcodes, trademarks, and regulatory information indicating it is a U.S. prescription drug product.*

FDA Label Image

Image 04

A Kaplan-Meier survival curve comparing the probability of overall survival over 24 months between Enfortumab Vedotin and Chemotherapy. The graph shows survival probabilities on the y-axis and duration of overall survival in months on the x-axis, including censored data points and number of patients at risk for each treatment group.*

FDA Label Image

Image 05

A Kaplan-Meier survival curve graph showing the probability of progression-free survival over time (in months) comparing Enfortumab Vedotin to chemotherapy. The plot includes censored data points and a table below indicating the number of subjects at risk at various time points for both treatment groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.